Almost three quarters of the new PBS listing submissions considered at the PBAC’s July meeting were given the green light, however many highly anticipated drugs have been delivered a blow
At its July meeting the PBAC ticked new indications and some financial requests, but knocked back others seeking higher prices
Last week the TGA approved a new antibiotic along with a new strength of a lung cancer drug plus generics, and OTCs
Rare disease patient groups have picked their favourite pharma with industry's overall reputation rising to levels not seen for five years - but companies still have plenty to improve on
Job movements continue across industry and it's not always for somewhere new - with two industry executives returning to companies where they've worked before
The Head of the TGA has threatened continued "strong compliance and enforcement action" after the Regulator issued its second significant fine in just over a month
This drug is still months off being filed for approval but there's already a booming black market with the Big Pharma that developed it taking a tough legal stand
Australia's largest radiopharma is determined that it's just getting started, increasing R&D spend twice as fast as revenue
Two new senior roles have been created, filled by an internal promotion and external hire, as the company expands its platform across Asia Pacific
New trial results could redefine how cancer patients are treated with two companies experiencing a massive boost in share price and market cap, with one pharma seeing its stock almost triple in value
The appointment of two experienced industry executives to major roles underlines this pharma's "commitment to investing in world-class talent"
Even with solid Phase 3 results showing a drug has a large benefit to patients, pharmas may hold off launching a drug in Australia over pricing
Despite strong challenges facing the pharmaceutical sector, companies have posted impressive revenue growth in the second quarter
Members of a class action alleging the pharma knowingly sold ineffective medicine must register or risk missing out on a possible settlement
